News

Filter

Current filters:

ImbruvicaHematology

AbbVie acquisition of Pharmacyclics will help secure future cash flows as Humira biosimilars loom, says analyst

06-03-2015

US drugmaker AbbVie’s acquisition of Pharmacyclics, valued at $21 billion, will help the company alleviate…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyHematologyHumiraImbruvicaMergers & AcquisitionsOncologyPharmacyclics

AbbVie to acquire Pharmacyclics, aiming to create leading hematological oncology franchise

AbbVie to acquire Pharmacyclics, aiming to create leading hematological oncology franchise

05-03-2015

US drugmaker AbbVie revealed late yesterday that it has reached an agreement to acquire US biopharma…

AbbVieBiotechnologyHematologyImbruvicaJohnson & JohnsonMergers & AcquisitionsNovartisOncologyPharmacyclics

FDA expands approval of Johnson & Johnson/Pharmacyclics' Imbruvica to Waldenstrom’s macroglobulinemia

FDA expands approval of Johnson & Johnson/Pharmacyclics' Imbruvica to Waldenstrom’s macroglobulinemia

30-01-2015

The US Food and Drug Administration has expanded approval of Johnson & Johnson and Pharmacyclics’ Imbruvica…

HematologyImbruvicaJohnson & JohnsonPharmaceuticalPharmacyclicsRegulationUSA

Back to top